Impact of renal denervation on quality of life (How does renal denervation contribute to improving hypertension treatment affected by poor medication adherence?)
© 2024. The Author(s), under exclusive licence to The Japanese Society of Hypertension..
The US Food and Drug Administration has approved renal denervation (RDN) as a new treatment option for hypertension (HT) because it not only has antihypertensive effects but also improves the quality of blood pressure (BP) reduction. RDN is expected to be increasingly used in clinical practice in the future. This review summarizes the impact of RDN on quality of life (QOL). Although the treatment of HT aims to improve life prognosis, the use of antihypertensive agents can impair QOL because of adverse effects and lifestyle changes associated with long-term medication use. Consequently, poor adherence to antihypertensive agents is a common problem and may be the most important issue affecting patient QOL. In RDN trials in patients taking antihypertensive agents, approximately 40% of patients had poor adherence to the drugs. Poor adherence is often the cause of resistant hypertension. Therefore, RDN should be well suited to treating HT and improving QOL. Studies have shown that approximately 30% of HT patients prefer RDN to drug treatment. Patients who prefer RDN are typically male and younger and have high BP, poor adherence, and a history of adverse effects of antihypertensive agents. We hope that RDN will improve not only life prognosis but also QOL in HT patients because of its benefits for adherence. Furthermore, we expect that in the future, RDN will be used in other sympathetic nervous system-related diseases, such as heart failure, atrial fibrillation, and sleep apnea syndrome.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Hypertension research : official journal of the Japanese Society of Hypertension - (2024) vom: 11. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Okamura, Keisuke [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adherence |
|---|
| Anmerkungen: |
Date Revised 25.04.2024 published: Print-Electronic ErratumIn: Hypertens Res. 2024 Apr 24;:. - PMID 38658650 Citation Status Publisher |
|---|
| doi: |
10.1038/s41440-024-01679-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370944542 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370944542 | ||
| 003 | DE-627 | ||
| 005 | 20240426234249.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41440-024-01679-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM370944542 | ||
| 035 | |a (NLM)38605140 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Okamura, Keisuke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of renal denervation on quality of life (How does renal denervation contribute to improving hypertension treatment affected by poor medication adherence?) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Hypertens Res. 2024 Apr 24;:. - PMID 38658650 | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to The Japanese Society of Hypertension. | ||
| 520 | |a The US Food and Drug Administration has approved renal denervation (RDN) as a new treatment option for hypertension (HT) because it not only has antihypertensive effects but also improves the quality of blood pressure (BP) reduction. RDN is expected to be increasingly used in clinical practice in the future. This review summarizes the impact of RDN on quality of life (QOL). Although the treatment of HT aims to improve life prognosis, the use of antihypertensive agents can impair QOL because of adverse effects and lifestyle changes associated with long-term medication use. Consequently, poor adherence to antihypertensive agents is a common problem and may be the most important issue affecting patient QOL. In RDN trials in patients taking antihypertensive agents, approximately 40% of patients had poor adherence to the drugs. Poor adherence is often the cause of resistant hypertension. Therefore, RDN should be well suited to treating HT and improving QOL. Studies have shown that approximately 30% of HT patients prefer RDN to drug treatment. Patients who prefer RDN are typically male and younger and have high BP, poor adherence, and a history of adverse effects of antihypertensive agents. We hope that RDN will improve not only life prognosis but also QOL in HT patients because of its benefits for adherence. Furthermore, we expect that in the future, RDN will be used in other sympathetic nervous system-related diseases, such as heart failure, atrial fibrillation, and sleep apnea syndrome | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Adherence | |
| 650 | 4 | |a Catheter-based renal sympathetic denervation | |
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Hypertension | |
| 650 | 4 | |a Preference | |
| 650 | 4 | |a Quality of Life | |
| 700 | 1 | |a Shimada, Hideaki |e verfasserin |4 aut | |
| 700 | 1 | |a Imazato, Keisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Sako, Hideto |e verfasserin |4 aut | |
| 700 | 1 | |a Udo, Akihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Taniguchi, Kenichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Morisaki, Shogo |e verfasserin |4 aut | |
| 700 | 1 | |a Imamura, Ichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Urata, Hidenori |e verfasserin |4 aut | |
| 700 | 1 | |a Arima, Hisatomi |e verfasserin |4 aut | |
| 700 | 1 | |a Miura, Shin-Ichiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hypertension research : official journal of the Japanese Society of Hypertension |d 1996 |g (2024) vom: 11. Apr. |w (DE-627)NLM075611406 |x 1348-4214 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:11 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41440-024-01679-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 11 |c 04 | ||